The Role of Advanced Glycation in Reduced Organic Cation Transport Associated with Experimental Diabetes

Tubular dysfunction is an important early manifestation of diabetic nephropathy. Reduced renal expression of organic cation transporters (OCTs) potentially contributes to impaired cation clearance in diabetes. This study examines the role of advanced glycation end-products (AGEs) in mediating these changes. Experimental diabetes was induced with streptozotocin (55 mg/kg). Rats were randomly treated with the AGE inhibitor aminoguanidine for 32 weeks. In a second protocol, diabetic rats were followed with and without low-dose insulin therapy (2 U/day) for 4 weeks. Expression of OCTs was determined by real-time RT-PCR (reverse transcription-polymerase chain reaction) and Western blotting. As a marker of cation transport, the fractional clearance of endogenous N-methylnicotinamide (NMN) was determined by high-performance liquid chromatography. Both short- and long-term diabetes was associated with reduced gene and protein expression of the three renal OCT isotypes. This was associated with a reduction in the fractional clearance of NMN compared with control animals by over 50%. These changes correlated with the accumulation of renal and plasma AGEs. Treatment with the AGE inhibitor aminoguanidine restored the expression of OCT-2 and OCT-3 in diabetic animals and normalized renal NMN clearance. NMN clearance was also improved in diabetic animals receiving low-dose insulin, correlating with a reduction in AGEs and improvement in effective renal plasma flow. These studies demonstrate an early impairment of expression of OCTs and cation clearance associated with diabetes. These changes correlate with the accumulation of AGEs and may be partly attenuated by an AGE inhibitor, implicating a role for AGEs in organic cation transport.

[1]  D. Buckley,et al.  Reduced Expression of Organic Cation Transporters rOCT1 and rOCT2 in Experimental Diabetes , 2004, Journal of Pharmacology and Experimental Therapeutics.

[2]  K. Pacak,et al.  Disprocynium24, a novel inhibitor of the extraneuronal monoamine transporter, has potent effects on the inactivation of circulating noradrenaline and adrenaline in conscious rat , 1996, Naunyn-Schmiedeberg's Archives of Pharmacology.

[3]  G. Jerums,et al.  The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat , 1995, Diabetologia.

[4]  A. Schinkel,et al.  Deficiency in the Organic Cation Transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in Mice Abolishes Renal Secretion of Organic Cations , 2003, Molecular and Cellular Biology.

[5]  Merlin C. Thomas,et al.  Role of advanced glycation end products in diabetic nephropathy. , 2003, Journal of the American Society of Nephrology : JASN.

[6]  Merlin C. Thomas,et al.  Reduced tubular cation transport in diabetes: prevented by ACE inhibition. , 2003, Kidney international.

[7]  S. Nigam,et al.  Organic anion and cation transporters occur in pairs of similar and similarly expressed genes. , 2003, Biochemical and biophysical research communications.

[8]  G. Jerums,et al.  Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat , 2003, Diabetologia.

[9]  Sang -Geon Kim,et al.  Effect of nitric oxide on the sinusoidal uptake of organic cations and anions by isolated hepatocytes , 2002, Archives of pharmacal research.

[10]  Merlin C. Thomas,et al.  Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. , 2002, Diabetes.

[11]  T. Miyata,et al.  Renal Proximal Tubular Metabolism of Protein-Linked Pentosidine, an Advanced Glycation End Product , 2002, Nephron.

[12]  Heinz Bönisch,et al.  Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3 , 2002, British journal of pharmacology.

[13]  M. Steffes,et al.  Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. , 2002, Kidney international.

[14]  H. Koepsell,et al.  Reduced Hepatic Uptake and Intestinal Excretion of Organic Cations in Mice with a Targeted Disruption of the Organic Cation Transporter 1 (Oct1 [Slc22a1]) Gene , 2001, Molecular and Cellular Biology.

[15]  D. Barlow,et al.  Impaired Activity of the Extraneuronal Monoamine Transporter System Known as Uptake-2 inOrct3/Slc22a3-Deficient Mice , 2001, Molecular and Cellular Biology.

[16]  R. Blantz,et al.  Ornithine decarboxylase, kidney size, and the tubular hypothesis of glomerular hyperfiltration in experimental diabetes. , 2001, The Journal of clinical investigation.

[17]  J. Biollaz,et al.  Validation of an HPLC method for the determination of urinary and plasma levels of N1-methylnicotinamide, an endogenous marker of renal cationic transport and plasma flow. , 2001, Journal of pharmaceutical and biomedical analysis.

[18]  V. Ganapathy,et al.  Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. , 2000, American journal of physiology. Renal physiology.

[19]  Takashi Okuda,et al.  Identification and characterization of the high-affinity choline transporter , 2000, Nature Neuroscience.

[20]  G. Jerums,et al.  Prevention of albuminuria by aminoguanidine or ramipril in streptozotocin-induced diabetic rats is associated with the normalization of glomerular protein kinase C. , 2000, Diabetes.

[21]  M. Cooper,et al.  The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? , 1999, Kidney international.

[22]  T. Miyata,et al.  Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. , 1999, Journal of the American Society of Nephrology : JASN.

[23]  S. Masuda,et al.  Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. , 1998, The Journal of pharmacology and experimental therapeutics.

[24]  L. Mazzetti,et al.  Semicarbazide-sensitive amine oxidase activity in the human heart. , 1998, Molecular genetics and metabolism.

[25]  G. Jerums,et al.  Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats , 1997, Diabetologia.

[26]  M. Cooper,et al.  Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury , 1997, Diabetologia.

[27]  E. Neilson,et al.  Role of protein kinase C and cyclic AMP/protein kinase A in high glucose-stimulated transcriptional activation of collagen α1 (IV) in glomerular mesangial cells , 1995 .

[28]  J. Baynes,et al.  N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. , 1995, Biochemistry.

[29]  E. Neilson,et al.  Role of protein kinase C and cyclic AMP/protein kinase A in high glucose-stimulated transcriptional activation of collagen alpha 1 (IV) in glomerular mesangial cells. , 1995, Journal of diabetes and its complications.

[30]  Yong Ming Li,et al.  Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[31]  W. Cefalu,et al.  Glycohemoglobin measured by automated affinity HPLC correlates with both short-term and long-term antecedent glycemia. , 1994, Clinical chemistry.

[32]  G. Jerums,et al.  Retardation by Aminoguanidine of Development of Albuminuria, Mesangial Expansion, and Tissue Fluorescence in Streptozocin-Induced Diabetic Rat , 1991, Diabetes.

[33]  E. Friedman,et al.  Advanced glycosylation end products in patients with diabetic nephropathy. , 1991, The New England journal of medicine.

[34]  G. Jerums,et al.  Glomerular Filtration Rate in Streptozocin-Induced Diabetic Rats: Role of Exchangeable Sodium, Vasoactive Hormones, and Insulin Therapy , 1990, Diabetes.

[35]  H. Be,et al.  Semicarbazide-sensitive amine oxidase activity in streptozotocin diabetic rats. , 1990 .

[36]  G. Jerums,et al.  Effects of genetic hypertension on diabetic nephropathy in the rat--functional and structural characteristics. , 1988, Journal of Hypertension.

[37]  P. Igarashi,et al.  Plasma hippurate in renal failure: high-performance liquid chromatography method and clinical application. , 1987, Nephron.

[38]  V. Pardo,et al.  Effect of duration of diabetes on the protection observed in the diabetic rat against gentamicin-induced acute renal failure. , 1984, Mineral and electrolyte metabolism.

[39]  T. Tomita,et al.  Streptozotocin Diabetic Rats Are Hypertensive Despite Reduced Hypothalamic Responsiveness , 1982, Hypertension.

[40]  B. Brenner,et al.  Glomerular hemodynamics in experimental diabetes mellitus. , 1981, Kidney international.

[41]  R. Buñag.  Validation in awake rats of a tail-cuff method for measuring systolic pressure. , 1973, Journal of applied physiology.

[42]  H. Oldershausen.  [Experimental diabetes mellitus]. , 1951, Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete.